Showing results (61-70 of 102) with videos related to
Sort By:
Pageof 11
Pharmacological Research|May 15, 2020
Complete neural stem cell (NSC) neuronal differentiation requires a branched chain amino acids-induced persistent metabolic shift towards energy metabolismFrancesco Bifari, Sissi Dolci, Emanuela Bottani, et al.Journal of Experimental & Clinical Cancer Research : CR|July 11, 2018
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor modelsAnais Del Curatolo, Fabiana Conciatori, Ursula Cesta Incani, et al.Proceedings of the National Academy of Sciences of the United States of America|April 29, 2026
Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinomaErika Testa, Clara Dezi, Francesca Lovat, et al.The Journal of Pathology|November 23, 2016
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2DMichele Simbolo, Andrea Mafficini, Katarzyna O Sikora, et al.Therapeutic Advances in Medical Oncology|November 12, 2025
PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevanceSara Pilotto, Lorenzo Belluomini, Federico Monaca, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2023
LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer GrowthOihane Erice, Shruthi Narayanan, Iker Feliu, et al.Journal for Immunotherapy of Cancer|September 20, 2019
Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3Rosalinda Trovato, Alessandra Fiore, Sara Sartori, et al.Oncotarget|May 29, 2014
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroupsMichele Simbolo, Matteo Fassan, Andrea Ruzzenente, et al.Journal of Translational Medicine|November 23, 2023
Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancerAntonio Agostini, Ilaria Guerriero, Geny Piro, et al.Cancer Immunology Research|June 30, 2026
Multinucleated giant cells in human pancreatic cancer are a distinct macrophage population undergoing a DNA damage response and associated with an aggressive tumor microenvironmentMarika Viatore, Rebecca Polidori, Anna Rita Putignano, et al.Pageof 11